DeMuro C. Two years of COVID-19: what has been the global impact on HRQoL and clinical outcomes? Presented at the Virtual ISPOR Europe 2021; November 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Walters MC, Tisdale JF, Mapara MY, Krishnamurti L, Kwiatkowski JL, Aygun B, Kasow KA, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher ME, Zhang X, Ho PR, Thompson AA, Kanter J. Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy. Presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 11, 2021. Atlanta, Georgia. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):7. doi: 10.1182/blood-2021-146905
Estes SJ, Poulos C, Xu Y, Botha W, Leach CA, Wrobleski KK, Gordon K, Missmer SA. A discrete choice experiment study of physicians' preference for treatments for endometriosis-associated pain - fertility and sterility (fertstert.org). Presented at the 2021 American Society for Reproductive Medicine Scientific Congress & Expo; October 17, 2021. Baltimore, MD. [abstract] Fertil Steril. 2021 Sep 1; 116(3):e205. doi: 10.1016/j.fertnstert.2021.07.561
Vass CM, Boeri M, Poulos C, Turner AJ. Matching and weighting in health preference research. Presented at the 2021 Virtual 12th Meeting of the International Academy of Health Preference Research; June 2021. [abstract] Patient. 2021 Jun 18; p.1-6. doi: 10.1007/s40271-021-00532-0
Dong OM, Friede K, Chanfreau C, Voora D. One-year cost-effectiveness of CYP2C19- guided de-escalation and escalation of P2Y12 inhibitors in veterans with acute coronary syndromes undergoing percutaneous coronary intervention. Presented at the American College of Cardiology’s Virtual 70th Annual Scientific Session and Exposition; May 15, 2021. [abstract] J Am Coll Cardiol. 2021 May; 77(18 Suppl 1):3416.
Motzer RJ, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Wang J, Pan J, Ayele Asfaw A, He CS, Mody K, Cella D. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). Presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4502.
Qin S, Nelson L, McLeod L, Ma J, López Sánchez B, Gamil M, Stevens M, Jane Scott J. Psychometric evaluation of the pediatric RSV severity and outcomes rating system version 7 (PRESORSv7.1, observer-reported and PRESORSv7 clinician- reported forms) scores in young children hospitalized with respiratory syncytial virus infection. Presented at the 2021 Virtual Visual ISOQOL 28th Annual Conference; October 12, 2021. [abstract] Qual Life Res. 2021; 30(Suppl 1):S16-7. doi: https://doi.org/10.1007/s11136-021-02976-1